Gilchrist Francis J, Brady Margo, Gallop Katy, Wild Diane J, Tabberer Maggie, Jacques Loretta, Lenney Warren
Department of Child Health, University Hospital of North Staffordshire, Stoke-on-Trent, UK.
J Asthma. 2012 Jun;49(5):552-6. doi: 10.3109/02770903.2012.672610. Epub 2012 Apr 10.
Although well reported in adults, there is relatively little data on how children with asthma and their parents describe their attitudes to the disease, expectations of therapy, and perception of treatment benefit. We investigated this to determine if they differed from reports by adults with asthma.
We recruited families with an asthmatic child (4-11 years) who had recently been prescribed a change in treatment [starting inhaled corticosteroid monotherapy (ICS) or changing from ICS to inhaled corticosteroid/long-acting β(2)-agonist combination therapy (ICS/LABA)]. Semi-structured interviews were conducted with the parents and the children if aged 7-11 years.
We interviewed 28 parents and 13 children. All children on ICS/LABA had been changed from ICS monotherapy because of poor asthma control. Pediatric asthma had a significant impact on the whole family and both parents and children hoped the new medication would improve symptoms, increase their participation in physical activities, and decrease unscheduled visits to the GP (General Practitioner)/hospital. Positive effects of treatment change were reported by both parents and children, particularly in those changing from ICS to ICS/LABA. The most commonly reported benefits were reduced cough and wheeze, increased participation in sport or play activities, and reduced rescue medication use. These effects resulted in fewer visits to the GP/hospital and better attendance at school.
While asthma symptoms prevent adults and children from participating in different types of activities (e.g., school, employment), children and their parents report the same benefits as previously reported in adults with asthma.
尽管成人哮喘已有大量报道,但关于哮喘儿童及其父母如何描述他们对疾病的态度、治疗期望以及对治疗益处的认知的数据相对较少。我们对此进行了调查,以确定他们与成年哮喘患者的报告是否存在差异。
我们招募了有哮喘儿童(4 - 11岁)的家庭,这些儿童最近接受了治疗方案的调整[开始吸入糖皮质激素单药治疗(ICS)或从ICS转换为吸入糖皮质激素/长效β₂受体激动剂联合治疗(ICS/LABA)]。对父母进行了半结构式访谈,7 - 11岁的儿童也参与了访谈。
我们采访了28名家长和13名儿童。所有接受ICS/LABA治疗的儿童均因哮喘控制不佳而从ICS单药治疗转换过来。儿童哮喘对整个家庭有重大影响,父母和孩子都希望新药物能改善症状、增加他们参与体育活动的机会,并减少不定期去看全科医生/医院的次数。父母和孩子都报告了治疗方案改变的积极效果,特别是那些从ICS转换为ICS/LABA的患者。最常报告的益处包括咳嗽和喘息减轻、参与体育或游戏活动增加以及急救药物使用减少。这些效果导致去看全科医生/医院的次数减少,上学出勤率提高。
虽然哮喘症状会阻止成人和儿童参与不同类型的活动(如上学、工作),但儿童及其父母报告的益处与先前成年哮喘患者报告的相同。